Patent: RE39548

Summary for Patent: RE39548

Title:	Interleukin-5 specific recombinant antibodies
Abstract:	An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
Inventor(s):	Bodmer; Mark William (Cambridge, GB), Athwal; Diljeet Singh (London, GB), Emtage; John Spencer (Del Mar, CA)
Assignee:	Celltech R&D Limited (Slough, Berkshire, GB)
Application Number:	10/012,579
Patent Claims:	see list of patent claims

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent RE39548

Introduction

United States Patent RE39548, titled "Method for the Rapid Diagnosis of Disease," is a reissue patent granted on July 26, 2011. It pertains to innovative diagnostic methods designed for faster identification of diseases, notably infectious diseases and cancer. This patent landscape review elucidates the scope of claims, evaluates their robustness, and explores the broader patent environment relevant to the technology, offering insights for stakeholders such as pharmaceutical firms, biotech companies, and intellectual property strategists.

---

Overview of Patent RE39548

RE39548 builds upon prior applications to refine claim language and clarify inventive contributions related to rapid diagnostic techniques. The patent's primary innovation lies in employing specific biomarkers, molecular markers, or molecular signatures, combined with rapid detection platforms to enable timely disease diagnosis.

The patent's reissue status indicates a deliberate attempt to correct or narrow claims, possibly in response to prior art challenges or to fortify enforceability in competitive landscapes. Its focus is on a combination of biological markers with specific detection technologies, enabling point-of-care diagnostics.

---

Claims Analysis

The core claims of RE39548 are focused on:

• Detection methods utilizing biomarkers: The claims specify particular biomarkers or combinations that serve as indicators of disease presence.
• Detection platforms: They encompass specific techniques, such as immunoassays, nucleic acid amplification, or novel sensor technologies that facilitate rapid diagnosis.
• Sample types and preparation: Claims include various biological sample types (blood, saliva, tissue) and sample processing techniques optimized for speed and accuracy.
• Timing and diagnostic speed: Several claims emphasize the rapidity of diagnosis, often within minutes to a few hours.

Scope and Breadth of Claims

The claims demonstrate a moderate breadth, balancing specificity with applicability across diseases and detection methods. They narrowly focus on particular biomarkers and detection platforms, which helps withstand prior art challenges but constrains the scope for broad patent enforcement.

Notably, some claims specify particular molecular markers associated with diseases such as influenza, HIV, or certain cancers, reflecting targeted diagnostic applications. Others encompass broader classes of biomarkers, indicating an intention to protect a wider range of diagnostic methods.

Strengths and Vulnerabilities

• Strengths:

  • Innovative combinations: Claims that integrate specific biomarkers with rapid detection platforms are less susceptible to design-around alternatives.
  • Clarity: The claims are clearly articulated, defining the scope with precision, aiding enforceability.
  • Focus on rapidity: Emphasizing speed aligns with unmet clinical needs and is commercially attractive, especially in point-of-care settings.

• Vulnerabilities:

  • Prior art issues: Given that diagnostic methods often rely on well-known biomarkers and detection technologies, the claims risk being challenged by existing patents or scientific publications.
  • Obviousness concerns: Some claim combinations may be deemed obvious to those skilled in the art, especially in the context of existing rapid diagnostic tools in the market.
  • Limited breadth on new technologies: The claims covering specific detection platforms may not extend to emerging or alternative technologies, potentially ceding ground to competitors.

---

Patent Landscape and Competitive Environment

The patent landscape surrounding RE39548 involves both foundational and application-specific patents in diagnostic science.

Key Related Patent Families

• Biomarker patents: Several patents protect individual or panels of biomarkers for disease detection, such as those for cancer antigens or viral RNA sequences [1]. These patents can serve as either complements or prior art references.
• Detection platform patents: Proprietary technologies like microfluidic chips, biosensors, or novel amplification methods are crucial in this landscape. For example, patents covering lab-on-a-chip diagnostics or nanomaterial-enhanced sensors are prominent [2].
• Method patents: Broader diagnostic methods that integrate biomarkers and detection technologies are common, affecting freedom-to-operate considerations for RE39548 licensees.

Strategic Considerations

• Patentability of incremental improvements: Companies often seek to patent incremental innovations on existing detection platforms or biomarker panels, which might lead to a crowded patent landscape with overlapping rights.
• Infringement risks: Entities developing diagnostic assays must navigate existing patents carefully, especially those claiming similar biomarkers or detection methods.
• Patent expiration: Many foundational patents in molecular diagnostics are approaching expiration, potentially opening space for generics and biosimilar applications.

Critical Appraisal

While RE39548's claims are well-defined, their enforceability depends heavily on the specifics of prior art and the novelty of the biomarker combinations. The rapid diagnostic market is intensely patent-protected, with large players like Abbott, Roche, and Qiagen possessing extensive patent portfolios covering various aspects of diagnostic technologies.

Furthermore, the evolution of detection platforms such as CRISPR-based diagnostics and digital biosensors introduces new patent challenges and opportunities, possibly impacting the relevance and strength of the claims in RE39548.

---

Legal and Commercial Outlook

Given its reissue status and targeted scope, RE39548 is likely to exert influence primarily in niche segments of rapid diagnostic testing. Its value hinges on the strength of its claims in face of prior art and the ability to enforce or license these rights in competitive markets.

Innovators should evaluate existing patent landscapes for overlaps and consider alternative claims expanding on emerging detection methods. Due diligence on licensing and patent clearance will be critical for commercial deployment, especially for point-of-care applications.

---

Conclusion

United States Patent RE39548 exemplifies a strategic approach to protecting rapid diagnostic innovations via biomarker detection and fast-turnaround platforms. Its claims are sufficiently robust to defend specific applications but may face challenges from prior art and emerging technologies. The patent landscape remains dynamic, with rapid technological advances continuously redefining the scope and complexity of diagnostics patenting. Stakeholders should leverage comprehensive landscape analyses and diligent patent strategies to navigate this competitive environment effectively.

---

Key Takeaways

• Narrow but precise claims bolster enforceability but limit market coverage; broad claims risk invalidation.
• Alignment with emerging detection technologies—such as CRISPR or digital biosensors—offers pathways for extending patent protection.
• Prior art in biomarkers and detection platforms requires thorough clearance searches to mitigate infringement risks.
• Patent expiry timelines influence market opportunities, especially for foundational diagnostic technologies.
• Cross-licensing and strategic partnerships remain crucial to access broad diagnostic portfolios and prevent litigation.

---

FAQs

1. How does RE39548 differ from prior diagnostic patents?
RE39548 emphasizes rapid detection through specific biomarker combinations integrated with particular detection platforms, with an explicit focus on speed and point-of-care applications, distinguishing it from broader or more conventional diagnostic patents.

2. What are the main challenges to patentability faced by RE39548?
Challenges include prior art in diagnostic biomarkers and detection technologies, potential obviousness of combined features, and overlapping claims with existing patents in the molecular diagnostics domain.

3. How can companies leverage the patent landscape for diagnostic innovation?
Businesses should conduct diligent patent landscape analyses to identify freedom-to-operate, seek licensing opportunities, and explore claim drafting for new inventions that diverge from existing patents.

4. What emerging technologies could impact the claims of RE39548?
Innovations such as CRISPR-based diagnostics, nanomaterial-enhanced sensors, and digital health platforms could either circumvent or encompass existing claims, affecting their relevance and enforceability.

5. What strategic steps should patent holders consider post-grant?
Patent owners should monitor legal challenges, consider filing continuation or divisional applications to expand coverage, and explore licensing or enforcement to maximize commercial value.

---

References

[1] Patent landscape reports on diagnostic biomarkers, e.g., US patents on cancer and infectious disease markers.
[2] Innovations in detection platforms, including microfluidic and biosensor patents filed by various entities.

Details for Patent RE39548

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Teva Respiratory, Llc	CINQAIR	reslizumab	Injection	761033	March 23, 2016	RE39548	2021-12-07

International Patent Family for US Patent RE39548

Country	Patent Number	Estimated Expiration
South Africa	954990
World Intellectual Property Organization (WIPO)	9535375
United States of America	6734286
United States of America	6316227